GRCE
NASDAQGrace Therapeutics Inc.
SectorHealth CareIndustryBiotechnology: Pharmaceutical Preparations
News · 26 weeks390%
2026-04-192026-10-11
Mix3090d
- Insider17(57%)
- SEC Filings9(30%)
- Other3(10%)
- Offering1(3%)
Latest news
25 items- INSIDERSEC Form 4 filed by Grace Therapeutics Inc.4 - Grace Therapeutics, Inc. (0001444192) (Issuer)
- INSIDERSEC Form 4 filed by Grace Therapeutics Inc.4 - Grace Therapeutics, Inc. (0001444192) (Issuer)
- INSIDERSEC Form 4 filed by Grace Therapeutics Inc.4 - Grace Therapeutics, Inc. (0001444192) (Issuer)
- INSIDERLarge owner Opaleye Management Inc. bought $16,404 worth of shares (7,849 units at $2.09) (SEC Form 4)4 - Grace Therapeutics, Inc. (0001444192) (Issuer)
- INSIDERAmendment: Large owner Opaleye Management Inc. bought $31,687 worth of shares (15,089 units at $2.10) (SEC Form 4)4/A - Grace Therapeutics, Inc. (0001444192) (Issuer)
- INSIDERLarge owner Opaleye Management Inc. bought $31,687 worth of shares (15,089 units at $2.10) (SEC Form 4)4 - Grace Therapeutics, Inc. (0001444192) (Issuer)
- INSIDERSEC Form 4 filed by Director Davis A Brian4 - Grace Therapeutics, Inc. (0001444192) (Issuer)
- INSIDERSEC Form 4 filed by Director Neugeboren Edward4 - Grace Therapeutics, Inc. (0001444192) (Issuer)
- INSIDERSEC Form 4 filed by Director Kavuru Vimal4 - Grace Therapeutics, Inc. (0001444192) (Issuer)
- INSIDERSEC Form 4 filed by Director Kottayil George4 - Grace Therapeutics, Inc. (0001444192) (Issuer)
- SECGrace Therapeutics Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders8-K - Grace Therapeutics, Inc. (0001444192) (Filer)
- INSIDERLarge owner Opaleye Management Inc. bought $31,896 worth of shares (15,229 units at $2.09) (SEC Form 4)4 - Grace Therapeutics, Inc. (0001444192) (Issuer)
- INSIDERChief Executive Officer Kohli Prashant bought $214,000 worth of shares (100,000 units at $2.14), increasing direct ownership by 468% to 121,357 units (SEC Form 4)4 - Grace Therapeutics, Inc. (0001444192) (Issuer)
- PRGrace Therapeutics to Participate in the H.C. Wainright 28th Annual Global Investment ConferencePRINCETON, N.J., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Grace Therapeutics, Inc. (NASDAQ:GRCE) (Grace Therapeutics or the Company), a late-stage, biopharma company advancing GTx-104, a clinical-stage, novel, injectable formulation of nimodipine being developed for IV infusion to address significant unmet medical needs in aSAH patients, today announced that Chief Executive Officer Prashant Kohli will participate and present in the H.C. Wainwright 28th Annual Global Investment Conference, to be held September 14-16, 2026 in New York, NY, at the Lotte New York Palace hotel. Mr. Kohli’s presentation will be available on demand from the conference website beginning Friday, September 11, 2026, and
- INSIDERSEC Form 4 filed by Chief Medical Officer Macdonald R. Loch4 - Grace Therapeutics, Inc. (0001444192) (Issuer)
- INSIDERSEC Form 4 filed by Principal Financial Officer Delaversano Robert J4 - Grace Therapeutics, Inc. (0001444192) (Issuer)
- INSIDERSEC Form 4 filed by VP Program Management Kumar Amresh4 - Grace Therapeutics, Inc. (0001444192) (Issuer)
- INSIDERSEC Form 4 filed by Chief Executive Officer Kohli Prashant4 - Grace Therapeutics, Inc. (0001444192) (Issuer)
- SECSEC Form EFFECT filed by Grace Therapeutics Inc.EFFECT - Grace Therapeutics, Inc. (0001444192) (Filer)
- SECSEC Form S-3 filed by Grace Therapeutics Inc.S-3 - Grace Therapeutics, Inc. (0001444192) (Filer)
- INSIDERLarge owner Opaleye Management Inc. bought $24,206 worth of shares (11,608 units at $2.09) (SEC Form 4)4 - Grace Therapeutics, Inc. (0001444192) (Issuer)
- SECGrace Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Grace Therapeutics, Inc. (0001444192) (Filer)
- PRGrace Therapeutics Announces First Quarter 2027 Financial Results, Provides Business UpdatePRINCETON, N.J., Aug. 13, 2026 (GLOBE NEWSWIRE) -- Grace Therapeutics, Inc. (NASDAQ:GRCE) (Grace Therapeutics or the Company), a late-stage, biopharma company advancing GTx-104, a clinical-stage, novel, injectable formulation of nimodipine being developed for IV infusion to address significant unmet medical needs in aSAH patients, today announced the financial results and business highlights for the three months ended June 30, 2026. "We continue to make progress on the requirements for resubmission of our New Drug Application (NDA) for GTx-104," said Prashant Kohli, Chief Executive Officer of Grace Therapeutics. "As previously disclosed, the U.S. Food and Drug Administration’s (FDA) Compl
- SECSEC Form 10-Q filed by Grace Therapeutics Inc.10-Q - Grace Therapeutics, Inc. (0001444192) (Filer)
- SECGrace Therapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Other Events, Financial Statements and Exhibits8-K - Grace Therapeutics, Inc. (0001444192) (Filer)
GRCE FAQ
5 questionsWhere does GRCE stock trade?
Grace Therapeutics Inc. (GRCE) is listed on NASDAQ.What sector and industry is GRCE in?
Grace Therapeutics Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.What are analysts saying about GRCE?
Grace Therapeutics Inc. has had 1 recent analyst action on file. The most recent action was from TD Cowen: Buy with a $1200.00 price target on 2025-05-02. Recent price targets cluster around $1200.00.What companies are similar to GRCE?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.), NVS (Novartis AG). Compare GRCE side-by-side with any of them on Quantisnow.How can I track GRCE on Quantisnow?
Quantisnow aggregates Grace Therapeutics Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow GRCE to receive live email and push alerts on every new disclosure.